Evoke Pharma Inc (EVOK) - Dilution Analysis

10-Q filing | 1.7M shares outstanding

10-Q filing | 1.6M shares outstanding

10-Q filing | 1.5M shares outstanding

10-K filing | 1.5M shares outstanding

10-Q filing | 1.4M shares outstanding

8-K filing: Evoke Pharma, Inc. entered into an amendment with certain affiliates of Nantahala Capital Management, LLC to reduce the exercise price with respect to 250,627 Series A Warrants and 250,627 Series C Warrants from $8.16 to $0.01, and expects to raise approximately $2.4 million in gross proceeds pursuant to this amendment and the exercise of Series B Warrants. ($4.8M proceeds)

S-3 filing: Evoke Pharma files an S-3 form offering common stock for up to $1.9 million via an at-the-market offering through Wainwright, in addition to a shelf offering for up to $50 million in various securities including common stock, preferred stock, and debt securities.

S-3 filing: This prospectus relates to the issuance of up to 3,266,107 shares of our common stock issuable upon the exercise of outstanding warrants and also relates to the issuance of up to 2,555,106 pre-funded warrants to purchase shares of common stock, which allows a Holder to elect to receive Pre-Funded Warrants upon exercise of Series A Warrants, Series B Warrants and Series C Warrants in lieu of shares of our common stock.

10-Q filing | 0.7M shares outstanding

8-K filing: Stock split 1-for-12 | Outstanding: 9,082,139 → 734,867

10-Q filing | 9.1M shares outstanding

10-K filing | 8.5M shares outstanding

8-K filing: Evoke Pharma, Inc. entered into an underwriting agreement for the issuance and sale of 5,134,731 common stock units at $0.68 per unit and 5,894,680 pre-funded warrant units at $0.6799 per unit, with an expected closing date of February 13, 2024. ($6.1M proceeds)

S-1/A filing: This S-1/A filing relates to a potential offering of common stock with an estimated net proceeds of $6.1 million, intended for working capital, general corporate purposes, and potential acquisitions, based on a price of $0.75 per share, with 3,343,070 shares of common stock outstanding as of September 30, 2023.

S-1/A filing: Evoke Pharma, Inc. is filing an S-1/A registration statement for the offering of common stock units and pre-funded warrant units, with each unit including common stock or pre-funded warrants and Series A, B, and C warrants.

S-1/A filing: This is an S-1/A filing for an offering that includes common stock, pre-funded warrants, and common warrants.

S-1/A filing: This is an S-1/A filing for a proposed offering of common stock, pre-funded warrants, and common warrants.

S-1/A filing: This is an S-1/A filing for Evoke Pharma, Inc. regarding the registration of common stock, pre-funded warrants, and common warrants, with Craig-Hallum Capital Group LLC and Laidlaw & Company (UK) Ltd. as underwriters.

S-1 filing: This is an S-1 filing for a proposed offering of common stock, pre-funded warrants and common warrants underwritten by LAIDLAW & COMPANY (UK) LTD.

10-Q filing | 3.3M shares outstanding

10-Q filing | 3.3M shares outstanding

10-Q filing | 3.3M shares outstanding

10-K filing | 3.1M shares outstanding

10-Q filing | 3.3M shares outstanding

10-Q filing | 3.2M shares outstanding

8-K filing: Stock split 1-for-12 | Outstanding: 40,116,877 → 3,343,073

10-Q filing | 40.1M shares outstanding

10-K filing | 32.9M shares outstanding

10-Q filing | 32.7M shares outstanding

10-Q filing | 32.4M shares outstanding

10-Q filing | 32.4M shares outstanding

10-K filing | 32.4M shares outstanding

S-3 filing: The company is filing an S-3 form to offer and sell up to $100 million in common stock, preferred stock and debt securities from time to time.

10-Q filing | 26.4M shares outstanding

10-Q filing | 26.0M shares outstanding

10-Q filing | 24.7M shares outstanding

10-K filing | 24.4M shares outstanding